Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

Long‐term efficacy and safety of bosutinib (≥4 years follow‐up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myeloid leukemia [CML], blast‐phase [BP, n = 64] CML, acute lym...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Hematol
Autors principals: Gambacorti‐Passerini, Carlo, Kantarjian, Hagop M., Kim, Dong‐Wook, Khoury, Hanna J., Turkina, Anna G., Brümmendorf, Tim H., Matczak, Ewa, Bardy‐Bouxin, Nathalie, Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Cortes, Jorge E.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5132035/
https://ncbi.nlm.nih.gov/pubmed/26040495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24034
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars